ZA202005311B - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer - Google Patents

7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Info

Publication number
ZA202005311B
ZA202005311B ZA2020/05311A ZA202005311A ZA202005311B ZA 202005311 B ZA202005311 B ZA 202005311B ZA 2020/05311 A ZA2020/05311 A ZA 2020/05311A ZA 202005311 A ZA202005311 A ZA 202005311A ZA 202005311 B ZA202005311 B ZA 202005311B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
derivatives
treatment
liver cancer
substituted
Prior art date
Application number
ZA2020/05311A
Inventor
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Sabine Hoves
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/054729 external-priority patent/WO2019166432A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA202005311B publication Critical patent/ZA202005311B/en

Links

ZA2020/05311A 2018-02-28 2020-08-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer ZA202005311B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (en) 2018-02-28 2019-02-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Publications (1)

Publication Number Publication Date
ZA202005311B true ZA202005311B (en) 2021-09-29

Family

ID=77908251

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/05311A ZA202005311B (en) 2018-02-28 2020-08-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Country Status (1)

Country Link
ZA (1) ZA202005311B (en)

Similar Documents

Publication Publication Date Title
EP3781564C0 (en) Pyridazine derivatives for the treatment of cancer
EP3894392A4 (en) Compositions and methods for the treatment of cancer
EP4010080C0 (en) Heterocyclic compounds for use in the treatment of cancer
IL276817A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
IL268676A (en) Inhibition of smarca2 for treatment of cancer
IL263793A (en) Compounds and compositions for the treatment of cancer
IL280587B (en) Flurocytidine derivatives and its composition for the treatment of cancer
SG11202108636SA (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
IL282313A (en) Abituzumab for the treatment of colorectal cancer
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
IL272147A (en) Methods and compositions for the treatment of cancer
EP3681498A4 (en) Methods and compositions for the treatment of cancer
IL286649A (en) Quinoline derivatives and their use for the treatment of cancer
IL280262A (en) Compositions and methods for the treatment of cancer
ZA202005311B (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
EP3846797A4 (en) Use of delta-tocotrienol for treating cancer
EP3630754B8 (en) Isoindoline-acetylene compounds for the treatment of cancer
EP3538102A4 (en) Inhibition of kmt2d for the treatment of cancer
EP3440134A4 (en) Lls compounds for treatment of cancer
AU2018900827A0 (en) Methods and compounds for the treatment of cancer
AU2018904604A0 (en) Methods and compositions for the treatment of cancer
AU2019900844A0 (en) Methods and compounds for the treatment of cancer
EP3876919A4 (en) Compositions for the treatment of cancer and other conditions